[1] ZHAN Yuanling YANG Jun XU Xiaodan CHEN Bo XIN Jie,.Effect of Buyang Huanwu Decoction on Hemorheology and Hemodynamics in Patients with Chronic Cerebral Insufficiency [J]. Modern Traditional Chinese Medicine, 2023, (06): 54-58. [doi: 10.13424/j.cnki.mtcm.2023.06.012]
Effect of Buyang Huanwu Decoction on Hemorheology and Hemodynamics in Patients with Chronic Cerebral Insufficiency
- Article number:
- 1672-0571(2023)06-0054-05
- Keywords:
- Key words:Buyang Huanwu decoction; Chronic cerebral ischemia; Hemodynamics; Hemorheology; Randomized controlled
- ZTFLH:
- R255.3
- Code:
- A
- Abstract:
- Abstract：Objective To explore the effect of Buyang Huanwu decoction on hemorheology and hemodynamics in patients with chronic cerebral blood supply insufficiency. Methods 88 patients with chronic cerebral ischemia admitted to our hospital from April 2019 to April 2022 were collected and randomly divided into a treatment group (44 cases, treated with conventional Western medicine and Buyang Huanwu decoction) and a control group (44 cases, treated with conventional Western medicine). Evaluate clinical efficacy, measure and compare changes in blood rheology, hemodynamics, and serum inflammatory factors between two groups of patients before and after treatment, and calculate the occurrence of adverse reactions such as drowsiness, gastrointestinal discomfort, and rash during the administration period. Results The total effective rate of the treatment group was significantly higher than that of the control group (P<0.05); After treatment, the plasma viscosity and hematocrit of the treatment group were significantly lower than those of the control group (P<0.05); After treatment, the average blood flow velocity of the vertebral artery, basilar artery, and middle cerebral artery in the treatment group was significantly higher than that in the control group (P<0.05); After treatment, the serum interleukin-23 (IL-23) and tumour necrosis factor-α(TNF-α) levels in the treatment group were significantly lower than those in the control group (P<0.05); There was no significant difference in the incidence of adverse reactions between the treatment group and the control group (P>0.05). Conclusion The combination of Buyang Huanwu decoction and conventional Western medicine treatment can significantly improve the hypercoagulable state of blood, restore intracranial hemodynamics, reduce inflammatory reactions, and enhance overall efficacy in patients with chronic cerebral blood supply insufficiency. Moreover, the combination of medication has no significant toxic effect.
References:
［1］Zhou F,Wang MD,Ju J,et al.Schizandrin A protects against cerebral ischemia-reperfusion injury by suppressing inflammation and oxidative stress and regulating the AMPK/Nrf2 pathway regulation［J］.American Journal of Translational Research,2019,11(1):199-209.
［2］Jeong JH,Kim JW,Choi DH.Safety and effectiveness of lumbar cerebrospinal fluid drainage to prevent delayed cerebral ischemia after Fisher grade 3 subarachnoid hemorrhage with minimal intraventricular hemorrhage［J］.Neuro-Chirurgie,2020,66(4):225-231.
［3］潘雯,张立敏,李茹,等.辽宁省农村地区40岁及以上人群颈动脉粥样硬化流行病学特征现状分析［J］.中国公共卫生,2021,37(1):92-96.
［4］贾妮,邢少娜,魏格玲,等.养脑通络汤治疗慢性脑供血不足肾虚血瘀型临床研究［J］.陕西中医药大学学报,2017,40(5):41-43.
［5］邓华,张选国,王凌,等.针刺联合阿司匹林、长春西汀治疗气虚型后循环缺血性眩晕30例［J］.陕西中医药大学学报,2019,42(6):89-91.
［6］张弛,段小英,蒲小兰.补阳还五汤加减结合手法治疗慢性脑供血不足的临床疗效观察［J］.中国全科医学,2012,15(28):3308-3309,3312.
［7］北京中西医结合学会卒中专业委员会.慢性脑缺血中西医结合诊疗专家共识［J］.中华医学信息导报,2018,33(22):24-25.
［8］郑筱萸.中药新药临床研究指导原则:试行［M］.北京:中国医药科技出版社,2002:28-30.
［9］金正龙,余涛,梁敏莹,等.通窍活血汤联合丁苯酞对老年慢性脑缺血患者血清S100β、 HMGB1、sICAM-1、CXCL12、Lp-PLA2的影响［J］.中药材,2021,44(5):1244-1248.
［10］吴正刚,高杰元,孙秋淩.半夏白术天麻汤加减结合尼莫地平片对慢性脑供血不足患者认知功能障碍及脑血流变化的影响［J］.国际中医中药杂志,2022,44(8):864-868.
［11］魏凯.补中益气汤加味联合长春西汀对气虚下陷型慢性脑供血不足患者血浆H2S、CBS水平的影响［J］.现代中西医结合杂志,2017,26(10):1059-1061.
［12］夏子禹,张艳,徐孙江.补阳还五汤干预社区慢性脑供血不足的疗效观察［J］.陕西中医,2015,36(12):1573-1574.
［13］王超,张咪,赵丽萍,等.基于网络药理学研究黄芪抗动脉粥样硬化的作用机制［J］.中成药,2022,44(3):987-994.
［14］付雪琴,兰瑞,邹旭欢,等.基于网络药理学研究丹参-川芎抗脑缺血再灌注损伤作用机制及试验验证［J］.中国畜牧兽医,2022,49(9):3643-3654.
［15］杜航,孙佳明,郭晓庆,等.地龙的化学成分及药理作用［J］.吉林中医药,2014,34(7):707-709.
［16］袁庆,殷孟兰,张彤,等.中药地龙治疗缺血性脑损伤的药理研究进展［J］.中西医结合心脑血管病杂志,2022,20(19):3574-3577.
［17］马艳春,吴文轩,胡建辉,等.当归的化学成分及药理作用研究进展［J］.中医药学报,2022,50(1):111-114.
［18］张莹莹,张科,宋崟,等.“川芎-当归”药对主要活性成分的网络药理学研究［J］.安徽医药,2023,27(1):19-24.
［19］杨晓东,苏晔,王诗卉,等.补阳还五汤加味治疗气虚血瘀型慢性脑供血不足患者疗效观察［J］.云南中医学院学报,2018,41(2):19-21,25.
［20］黄婷婷,吴海科,练梦结,等.不同频率重复经颅磁刺激联合补阳还五汤对气虚血瘀型卒中患者运动功能的疗效观察［J］.实用医学杂志,2023,39(4):499-504.
［21］金平,王经英,邢小炜,等.慢性脑缺血大鼠脑组织IL-1β、IL-6、TNF-α及β-淀粉样蛋白1-42的表达研究［J］.浙江医学,2019,41(5):419-423.
［22］李印珊.补中益气汤化裁方治疗CSA眩晕的疗效分析［J］.现代中医药,2020,40(3):57-60,64.
［23］李晶,张妮.艾地苯醌联合尼麦角林治疗慢性脑缺血头晕患者的疗效及对患者氧化应激的影响［J］.医学临床研究,2021,38(4):484-487.
［24］郁洁,洪侃,王卓,等.逐瘀通脉胶囊结合尼莫地平治疗老年慢性脑供血不足临床疗效研究［J］.中华中医药学刊,2021,39(9):208-211.
［25］王琳,齐立,何伟,等.急性脑梗死患者血清IL-23 IL-35与颈动脉粥样硬化 斑块稳定性的关系［J］.河北医学,2019,25(8):1312-1316.
Memo
基金项目：陕西省自然科学基础项目（2018JM7131）